Tag Archives: Fierce

Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027  Fierce Pharma Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook  CNBC Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop  Investor’s Business Daily Merck to Lay Off Workers and Narrows Guidance as Earnings Fall – WSJ  The Wall Street Journal Our Q2 2025 financial results  Merck.com …

Celcuity’s breast cancer combo hits goals, teeing up FDA filing  Fierce Biotech Celcuity Stock Triples on Positive Breast Cancer Treatment Study  Yahoo Finance Celcuity’s triple cancer drug combo beats AstraZeneca in halting cancer progression, shows study  Mint Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche  Endpoints News Gedatolisib Triplet Boosts Progression-Free Survival in Breast Cancer  Curetoday Source link

IN A NUTSHELL 🚀 Trump unveils a comprehensive AI Action Plan, aiming to slash bureaucratic red tape and boost American innovation. 🌐 The plan emphasizes enhancing export capabilities and constructing billion-dollar infrastructure projects to secure U.S. dominance. 🔧 Fast-tracking permits for data centers and launching workforce programs are key strategies to advance the AI agenda. 📈 The administration’s efforts focus …

NASA’s Sahara Shock: The Desert’s Mysterious Greening Sparks Fierce Battle Between Climate Optimists, Deniers, and Geopolitical Hawks  Rude Baguette Source link

Replimune’s shares crater as FDA rejects melanoma drug  Fierce Biotech Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance  statnews.com Replimune drug rejected by FDA; Omega raises $647M biotech fund  Yahoo Finance Replimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment  BioSpace Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment  Barron’s Source link

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy  Fierce Biotech We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress  statnews.com Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug  Yahoo Finance Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths  The New York Times …

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion  Fierce Pharma BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial  BioSpace Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes  Endpoints News Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here’s What Investors Are Thinking  Stocktwits Luspatercept Plus …